Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515112 · ClinicalTrials.gov registry record · Phase 2
Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00515112 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 6 participants.
The verdict
NCT00515112, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether prostate cancer growth can be slowed in patients who receive Androgel® 1% at 10 gram dose.
Interventions
- DRUG placebo
- DRUG AndroGel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515112
The ClinicalTrials.gov registry entry for NCT00515112 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00515112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00515112 about?
NCT00515112 is a clinical study titled "Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer". The purpose of this study is to determine whether prostate cancer growth can be slowed in patients who receive Androgel® 1% at 10 gram dose.
What is the current status of trial NCT00515112?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2007-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00515112?
The interventions under investigation include: placebo (DRUG), AndroGel (DRUG).
Who is sponsoring clinical trial NCT00515112?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.